Psoriasis: Latest
- Fast Five Quiz: The Psychosocial Burden of Psoriasis
- Experimental Topical Drug Shows Promise for AD, Psoriasis
- Fast Five Quiz: Multiple Sclerosis Comorbidities
- Keeping Injectable Products in Cosmetic Dermatology Safe
- Paradoxical Eczema Risk Low With Biologic Psoriasis Tx
- Reducing CVD Morbidity and Mortality in Psoriasis and PsA
- Alert Roflumilast Foam Gets Nod for Seborrheic Dermatitis
- When to Initiate Systemic Treatment for Plaque Psoriasis
- Bimekizumab Promising for Palmoplantar Pustular Psoriasis
- Tape Strips Detect Hidradenitis Suppurativa Biomarkers
- How to Develop a Patient Referral Program
- Patients With hEDS Report Skin Laxity, Scarring
- Axial Spondyloarthritis Highlights From ACR 2023
- Analysis Supports Link Between Psoriasis and OSA
- MSWS 2023 Misdiagnoses Among Challenges in Managing Cutaneous Lymphoma
- Nail Psoriasis in Black Patients Often Overlooked
- HS: Positive Results Reported With Anti-IL17A/F Therapies
- A Pill for Psoriasis: The Latest Oral Medications
- Parent Concerns a Factor When Treating Patients With AD
- ACR 2023 IV Secukinumab Trials Hit Primary Endpoints in PsA, AxSpA
- ACR 2023 First Referral Guide Issued for Axial Spondyloarthritis
- ACR 2023 Apremilast Beats Placebo in Early PsA Affecting Few Joints
- AAD Updates Guidelines for Managing AD
- ACR 2023 TNF Blockers Not Associated With Poorer Pregnancy Outcomes
- Palmoplantar Pustulosis: Treatment Challenges
- Teasing Apart Multiple Biologic Failure in Psoriasis, PsA
- Ready to Start Engaging on Social Media?
- Shingles Prevention in Immunocompromised Dermatology Patients
- Alert FDA Approves First Ustekinumab Biosimilar